Targeting Folate Receptor Alpha Provides Therapeutic Benefits for Platinum-Resistant Ovarian Cancer
June 5th 2023Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.
Watch
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC
June 5th 2023Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
Read More
COVID-19 Infection Could Be Detected in Lungs, Heart, Causing Inflammatory Damage
June 2nd 2023Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.
Read More
Psychedelic Research May Support Unprecedented End-of-Life Care for Patients With Cancer
June 1st 2023Psilocybin and other psychedelics hold promise in treating anxiety, depression, substance abuse and addiction, posttraumatic stress disorder, obsessive compulsive disorder, headaches, and chronic pain disorders.
Read More